Groupon, Inc. (GRPN) Traders Eye Earnings Upside

It appears call buyers have their sights set on Groupon Inc (GRPN) today

by Alex Eppstein

Published on Apr 24, 2015 at 3:02 PM

Groupon Inc (NASDAQ:GRPN) is sitting slightly above breakeven this afternoon at $7.16. In the options pits, calls are running at a slightly quicker-than-usual intraday pace, and outstrip puts by a nearly 5-to-1 margin.

GRPN's most active option by far is the weekly 5/8 7-strike call, where 3,355 contracts are on the tape. It's possible traders are buying fresh positions here, expecting the shares to extend their lead atop the $7 level through the close on Friday, May 8, when the weekly options expire.

If this is the case, the speculators may be counting on GRPN to stage a post-earnings rally. The coupon firm will report quarterly results after the close on Tuesday, May 5 -- just three days before the aforementioned calls cease trading.

GRPN tends to make big moves following these events. Over the last eight quarters, the stock has averaged a move of 15.4% in the session immediately after reporting. Currently, based on straddle data, the options market is pricing in a slightly more modest 13.5% move.

On the charts, Groupon Inc (NASDAQ:GRPN) has been trendling lower since hitting a late-February high of $8.37. On a relative-strength basis, over the past two months, the shares have underperformed the broader S&P 500 Index (SPX) by 14 percentage points.

A Schaeffer's exclusive!

The Expert's Guide

Access your FREE trading earning announcements before it's too late!


 
 

Partnercenter


NEW! Explore Schaeffer’s Partners' deals and get connected to top online brokerages with deals tailored exclusively for our readers.  Get answers to your questions regarding transfer fees, commission rates, programs and available discounts related to online trading services.

MORE | MARKETstories


The Latest Investor's Guide to Precious Metals
Learn how to protect savings and maximize returns by investing in precious metals.
Patent Lawsuit Loss Sends AMRN Stock Spiraling
Amarin just lost a major U.S. patent lawsuit for its heart drug Vascepa
RH Stock Sinks Despite Earnings Beat
J.P. Morgan Securities and Cowen and Company cut their price targets
The Latest Investor's Guide to Precious Metals
Learn how to protect savings and maximize returns by investing in precious metals.